二价mRNA疫苗预防有症状SARS-CoV-2感染的效果——扩大社区检测可及性项目,美国,2022年9月至11月
利用美国扩大社区检测可及性(ICATT)项目中2022年9月14日至11月11日成人有症状且无免疫抑制状况的360,626份核酸检测数据,评估二价(含Omicron BA.4/BA.5)加强针对有症状SARS-CoV-2感染的相对疫苗有效性(rVE)。与至少2剂单价疫苗相比,距末次单价接种2-3个月和≥8个月者rVE分别为18-49岁30%和56%、50-64岁31%和48%、≥65岁28%和43%。二价mRNA加强针为既往仅接种单价疫苗的免疫功能正常者提供额外保护,且相对获益随末次单价接种时间延长而增加。
要点
- 成人有症状且无免疫抑制状况者,二价加强针相对至少2剂单价疫苗的rVE在18-49岁为30%-56%。
- 50-64岁rVE为31%-48%,≥65岁为28%-43%,均随末次单价接种时间延长而升高。
- 二价mRNA加强针为既往仅接种单价疫苗的免疫功能正常者提供额外保护。
核心结论
- 二价mRNA加强针为既往仅接种单价疫苗的免疫功能正常成人提供针对有症状SARS-CoV-2感染的额外保护,相对获益随末次单价疫苗接种时间延长而增加。
- 及时接种COVID-19疫苗(包括符合条件时接种二价加强针)对最大化保护至关重要。
研究设计与样本
- 利用美国扩大社区检测可及性(ICATT)全国SARS-CoV-2检测项目的数据进行分析。
- 纳入2022年9月14日至11月11日在9,995家零售药店进行的360,626份核酸检测,对象为≥18岁、检测时有COVID-19一致症状且无免疫抑制状况的成人。
- 比较二价加强针与至少2剂单价疫苗的相对疫苗有效性(rVE)。
主要发现
- 距末次单价接种2-3个月者,二价加强针相对至少2剂单价疫苗的rVE在18-49岁为30%,50-64岁为31%,≥65岁为28%。
- 距末次单价接种≥8个月者,rVE在18-49岁为56%,50-64岁为48%,≥65岁为43%。
- 相对获益随末次单价疫苗接种时间延长而增加。
关键数值与推荐
- 2022年9月1日,ACIP推荐二价COVID-19 mRNA疫苗(含SARS-CoV-2原始株和Omicron BA.4/BA.5株成分),用于已完成至少基础系列单价疫苗≥2个月的≥12岁(Pfizer-BioNTech)和≥18岁(Moderna)人群。
- 2022年10月12日,推荐范围扩大至5-11岁儿童。
临床怎么用
- 免疫功能正常成人既往仅接种单价疫苗者,符合条件时接种二价加强针可获得针对有症状SARS-CoV-2感染的额外保护。
- 保持COVID-19疫苗接种更新(包括符合条件时接种二价加强针)对最大化保护至关重要。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On September 1, 2022, bivalent COVID-19 mRNA vaccines, composed of components from the SARS-CoV-2 ancestral and Omicron BA.4/BA.5 strains, were recommended by the Advisory Committee on Immunization Practices (ACIP) to address reduced effectiveness of COVID-19 monovalent vaccines during SARS-CoV-2 Omicron variant predominance (1). Initial recommendations included persons aged ≥12 years (Pfizer-BioNTech) and ≥18 years (Moderna) who had completed at least a primary series of any Food and Drug Administration-authorized or -approved monovalent vaccine ≥2 months earlier (1). On October 12, 2022, the recommendation was expanded to include children aged 5-11 years. At the time of recommendation, immunogenicity data were available from clinical trials of bivalent vaccines composed of ancestral and Omicron BA.1 strains; however, no clinical efficacy data were available. In this study, effectiveness of the bivalent (Omicron BA.4/BA.5-containing) booster formulation against symptomatic SARS-CoV-2 infection was examined using data from the Increasing Community Access to Testing (ICATT) national SARS-CoV-2 testing program.* During September 14-November 11, 2022, a total of 360,626 nucleic acid amplification tests (NAATs) performed at 9,995 retail pharmacies for adults aged ≥18 years, who reported symptoms consistent with COVID-19 at the time of testing and no immunocompromising conditions, were included in the analysis. Relative vaccine effectiveness (rVE) of a bivalent booster dose compared with that of ≥2 monovalent vaccine doses among persons for whom 2-3 months and ≥8 months had elapsed since last monovalent dose was 30% and 56% among persons aged 18-49 years, 31% and 48% among persons aged 50-64 years, and 28% and 43% among persons aged ≥65 years, respectively. Bivalent mRNA booster doses provide additional protection against symptomatic SARS-CoV-2 in immunocompetent persons who previously received monovalent vaccine only, with relative benefits increasing with time since receipt of the most recent monovalent vaccine dose. Staying up to date with COVID-19 vaccination, including getting a bivalent booster dose when eligible, is critical to maximizing protection against COVID-19 (1).
引用
- Link-Gelles R, Ciesla AA, Fleming-Dutra KE, et al. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36454688. doi:10.15585/mmwr.mm7148e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。